Literature DB >> 16291752

Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis.

Elizabeth A Noton1, Rita Colnaghi, Sharon Tate, Carlene Starck, Ana Carvalho, Paul Ko Ferrigno, Sally P Wheatley.   

Abstract

Survivin is a protein with proposed roles in cell division and apoptosis. Transcripts encoding splice variants of human survivin have been described and their expression correlated with cancer progression. As survivin forms homodimers in vitro, it has been suggested that these isoforms could interfere with wild type function by forming heterodimers. Here we show that survivin-2beta and survivin-deltaEx3 can interact with wild type survivin but have reduced affinity for the partner protein of survivin, borealin, and thus do not localize with the chromosomal passenger complex in vivo. Furthermore, we demonstrate that overexpression of survivin-2beta-green fluorescent protein (GFP) or survivin-deltaEx3-GFP does not impede cell cycle progression. We also report that wild type survivin, but not survivin-2beta-GFP or survivin-deltaEx3-GFP, can rescue cell proliferation inhibited by small interfering RNA-mediated survivin depletion. These data suggest that, despite their ability to interact with wild type survivin, neither of these isoforms acts as its competitor during mitosis nor has an essential function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291752     DOI: 10.1074/jbc.M508773200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.

Authors:  Pablo E Vivas-Mejia; Cristian Rodriguez-Aguayo; Hee-Dong Han; Mian M K Shahzad; Fatma Valiyeva; Mineko Shibayama; Arturo Chavez-Reyes; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2011-04-21       Impact factor: 12.531

Review 2.  Survivin study: an update of "what is the next wave"?

Authors:  Fengzhi Li; Xiang Ling
Journal:  J Cell Physiol       Date:  2006-09       Impact factor: 6.384

3.  Induction of apoptosis of human colon cancer cells by siRNA recombinant expression vector targeting survivin gene.

Authors:  Ming Cai; Guobin Wang; Kaixiong Tao; Changxue Cai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-02-18

4.  The role of survivin in diagnosis, prognosis and treatment of breast cancer.

Authors:  Yong-Gang Lv; Fang Yu; Qing Yao; Jiang-Hao Chen; Ling Wang
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

5.  Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.

Authors:  Makito Tanaka; Marcus O Butler; Sascha Ansén; Osamu Imataki; Alla Berezovskaya; Lee M Nadler; Naoto Hirano
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

6.  Expression of survivin and its four splice variants in colorectal cancer and its clinical significances.

Authors:  Quan-Xing Ge; Yu-Yuan Li; Yu-Qiang Nie; Wen-Ge Zuo; Yan-Lei Du
Journal:  Med Oncol       Date:  2013-03-15       Impact factor: 3.064

7.  Expression of survivin and its splice variants in gastric cancer.

Authors:  Zhengjiang Cheng; Lihua Hu; Wenrong Fu; Qin Zhang; Xiaofeng Liao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-08

8.  Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.

Authors:  T Iwasa; I Okamoto; K Takezawa; K Yamanaka; T Nakahara; A Kita; H Koutoku; M Sasamata; E Hatashita; Y Yamada; K Kuwata; M Fukuoka; K Nakagawa
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 9.075

9.  Liaisons between survivin and Plk1 during cell division and cell death.

Authors:  Rita Colnaghi; Sally P Wheatley
Journal:  J Biol Chem       Date:  2010-04-28       Impact factor: 5.157

10.  Identification and characterization of PNRC splicing variants.

Authors:  Yuanzhong Wang; Yuping Li; Bin Chen; Yan Zhang; Guiyu Lou; Shiuan Chen; Dujin Zhou
Journal:  Gene       Date:  2008-07-25       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.